{'fraction_non_alphanumeric': 0.056179775280898875, 'fraction_numerical': 0.028089887640449437, 'mean_word_length': 6.202020202020202, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[6S]‐5‐methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild‐type 677C→T polymorphism of methylenetetrahydrofolate reductase

Background and purpose:  5,10‐Methylenetetrahydrofolate reductase (MTHFR) is responsible for the synthesis of 5‐methyltetrahydrofolate (5‐MTHF). The 677C→T mutation of MTHFR reduces the activity of this enzyme. The aim of this study was, first, to compare pharmacokinetic parameters of [6S]‐5‐MTHF and folic acid (FA) in women with the homozygous (TT) and wild‐type (CC) 677C→T mutation, and second, to explore genotype differences. The metabolism of [6S]‐5‐MTHF and FA was evaluated by measuring plasma folate derivatives.